Provided by Tiger Trade Technology Pte. Ltd.

Aytu BioScience, Inc.

2.07
-0.0200-0.96%
Post-market: 2.070.00000.00%16:10 EDT
Volume:15.80K
Turnover:33.04K
Market Cap:22.49M
PE:-1.78
High:2.15
Open:2.08
Low:2.06
Close:2.09
52wk High:3.07
52wk Low:1.80
Shares:10.87M
Float Shares:8.88M
Volume Ratio:0.44
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1600
EPS(LYR):-1.1600
ROE:-52.55%
ROA:-4.54%
PB:0.64
PE(LYR):-1.78

Loading ...

Aytu Biopharma Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Reuters
·
Sep 23

Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth

TradingKey
·
Sep 23

Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales

Reuters
·
Sep 23

Aytu BioPharma Q4 EPS $0.00 Beats $(0.33) Estimate, Sales $16.106M Beat $12.276M Estimate

Benzinga Earnings
·
Sep 23

Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate

Benzinga Earnings
·
Sep 23

Aytu BioPharma Q4 FY26 Net Loss Narrows to USD 15,000; Revenue Rises 6.4% to USD 16.1 Million vs Q4 FY25

Reuters
·
Sep 23

Aytu Biopharma Q4 Gross Profit USD 10.409 Million

THOMSON REUTERS
·
Sep 23

Aytu Biopharma Q4 Net Income USD -15 Thousand

THOMSON REUTERS
·
Sep 23

Aytu Biopharma Q4 EPS USD 0

THOMSON REUTERS
·
Sep 23

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 21

Aytu Biopharma Inc Expected to Post a Loss of 32 Cents a Share - Earnings Preview

Reuters
·
Sep 19

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 18

Aytu Biopharma Updates Financial Calendar with Fiscal 2026 Results Release and Conference Call

Reuters
·
Sep 17

Aytu Biopharma - Co and Lannett Terminate Metadate Agreement Effective June 23, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 26

Aytu Biopharma - to Continue Selling Existing Metadate Inventory and Pay Royalties Until Sales Cease - SEC Filing

THOMSON REUTERS
·
Jun 26

Aytu BioPharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 11

Aytu BioPharma to present at Planet MicroCap Las Vegas 2026 investor conference fireside Q&A

Reuters
·
Jun 02

Aytu BioPharma to present at Lytham Partners Spring Investor Conference

Reuters
·
May 19

Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)

TIPRANKS
·
May 14

Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14